Evidence map›Paper›PMID 23824800›Full record

ArticleJournal of virology2013

Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Joseph T Bruder, Ping Chen, Elena Semenova, Charlie A Thomas, Svetlana Konovalova, Greg Ekberg, Damodar Ettyreddy, Duncan McVey, Jason G Gall, C Richter King and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Profiling the Targets of Protective CD8Molecular therapy. Methods & clinical development · 2017
    Article
  5. Article
  6. Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Joseph T BruderGenVec, Inc, Gaithersburg, Maryland, USA. joetbruder@gmail.com
Ping Chen
Elena Semenova
Charlie A Thomas
Svetlana Konovalova
Greg Ekberg
Damodar Ettyreddy
Duncan McVey
Jason G Gall
C Richter King
Douglas E Brough
GenVec · US

Funding

Novel Ad5 Malaria Vaccine That Circumvents Pre-existing Ad5 ImmunityR43AI077309 · NIAID · GENVEC, INC. · PI BRUDER, JOSEPH T · 2008 to 2009
$600k
NIAID NIH HHS 1R43 AI077309-01NIAID NIH HHS R43 AI077309
6 · The paper itself

Abstract

We have generated hexon-modified adenovirus serotype 5 (Ad5) vectors that are not neutralized by Ad5-specific neutralizing antibodies in mice. These vectors are attractive for the advancement of vaccine products because of their potential for inducing robust antigen-specific immune responses in people with prior exposure to Ad5. However, hexon-modified Ad5 vectors displayed an approximate 10-fold growth defect in complementing cells, making potential vaccine costs unacceptably high. Replacing hypervariable regions (HVRs) 1, 2, 4, and 5 with the equivalent HVRs from Ad43 was sufficient to avoid Ad5 preexisting immunity and retain full vaccine potential. However, the resulting vector displayed the same growth defect as the hexon-modified vector carrying all 9 HVRs from Ad43. The growth defect is likely due to a defect in capsid assembly, since DNA replication and late protein accumulation were normal in these vectors. We determined that the hexon-modified vectors have a 32°C cold-sensitive phenotype and selected revertants that restored vector productivity. Genome sequencing identified a single base change resulting in a threonine-to-methionine amino acid substitution at the position equivalent to residue 342 of the wild-type protein. This mutation has a suppressor phenotype (SP), since cloning it into our Ad5 vector containing all nine hypervariable regions from Ad43, Ad5.H(43m-43), increased yields over the version without the SP mutation. This growth improvement was also shown for an Ad5-based hexon-modified vector that carried the hexon hypervariable regions of Ad48, indicating that the SP mutation may have broad applicability for improving the productivity of different hexon-modified vectors.

Indexed as

Genetic VectorsAdenoviruses, HumanAmino Acid SequenceAmino Acid SubstitutionAnimalsAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsCytokinesFemaleGenes, ViralHEK293 CellsHumansMiceMice, Inbred BALB CMolecular Sequence DataAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsCytokineshexon capsid protein, AdenovirusViral Vaccines

Identifiers

PMID23824800
PMCPMC3754123
OpenAlexW2128299354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.